A recent publication in the oncology field revealed that high blood levels of soluble OX40 indicate reduced survival in patients with advanced colorectal cancer (CRC).
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).
The Idylla™ MSI Assay provides information on the MSI 1 status2,3,4 (i.e. MSI-High or Microsatellite stable) of a tumour within approximately 150 minutes from just one slice of FFPE5 tumour tissue, without requiring a reference sample.
At the advanced edge of oncology, rapid access to accurate data on disease state is vital. The fully automated Idylla™ system, in combination with the Idylla™ Mutation Assays (tissue and liquid biopsy), is the future of diagnosis and monitoring.